Prosecution Insights
Last updated: May 29, 2026

Examiner: DUNN, MCKENZIE A

Tech Center 1600 • Art Units: 1632 1636 1678

This examiner grants 57% of resolved cases

Performance Statistics

57.1%
Allow Rate
-2.9% vs TC avg
114
Total Applications
+50.2%
Interview Lift
1436
Avg Prosecution Days
Based on 70 resolved cases, 2023–2026

Rejection Statute Breakdown

6.4%
§101 Eligibility
8.0%
§102 Novelty
67.3%
§103 Obviousness
6.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18257838 ANTITHROMBIN HEPARAN SULFATE FOR DETECTION AND TREATMENT OF CANCER Non-Final OA The Regents of the University of California
17642374 BIOMARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND MOTOR NEURON DISEASES Final Rejection Northwestern University
18263899 METHODS OF ADJUSTING THE PH OF A CELL CULTURE MEDIUM Non-Final OA Bayer HealthCare LLC
17205649 COMPOSITE PARTICLE FOR IMMUNOCHROMATOGRAPHY, METHOD FOR MANUFACTURING THE SAME, AND IMMUNOCHROMATOGRAPHY Final Rejection FUJIFILM Corporation
17612919 LINKED BODY FOR FLUORESCENT LABELING AGENTS Non-Final OA Konica Minolta, Inc.
17339889 SYSTEMS AND METHODS FOR ANALYTE DETECTION USING ELECTROMAGNETICALLY INDUCED RESONANCE Final Rejection The Brigham and Women's Hospital, Inc.
15963271 DIAGNOSING MULTIPLE SCLEROSIS Final Rejection Oxford University Innovation Limited
17288849 COMPOSITIONS AND METHODS FOR SELECTING BIALLELIC GENE EDITING Non-Final OA United States Government As Represented By The Department of Veterans Affairs
17963376 NANOZYME LINKED BIOASSAY AND ASSOCIATED METHODS Non-Final OA Washington State University
17606981 Elucidating a Proteomic Signature for the Detection of Intracerebral Aneurysms Non-Final OA Icahn School of Medicine at Mount Sinai
18270157 OPTOELECTRONIC CHIP Non-Final OA INTERHERENCE GMBH
18192286 UVEAL MELANOMA TREATMENT USING SEA-CD40 Non-Final OA Seagen Inc.
17998691 DETERMINATION OF DISEASE-SPECIFIC PROTEIN AGGREGATES IN STOOL SAMPLES Non-Final OA FORSCHUNGSZENTRUM JUELICH GMBH
18185632 PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT Non-Final OA Compugen Ltd.
18127887 IMAGE QUANTIFICATION SYSTEM FOR ESTIMATION OF VIRAL LOAD BASED ON DETECTION BY RAPID ANTIGEN TEST Non-Final OA Hai Kang Life Corporation Limited
18024620 MARKERS FOR PREDICTING CORONAVIRUS DISEASE 2019 (COVID-19) IMMUNE CHECKPOINT STORM, APPLICATION AND KIT THEREOF Non-Final OA Beijing Immupeutics Medicine Technology Limited
17160196 METHODS FOR DEPLETION AND ENRICHMENT Final Rejection Veravas, Inc.
18159857 FLUORESCENCE COUNTING SYSTEM FOR QUANTIFYING VIRUSES OR ANTIBODIES ON AN IMMOBILIZED METAL SUBSTRATE BY USING AN ANTIGEN-ANTIBODY REACTION Non-Final OA MYTECH CO. LTD.
17754313 BIOMARKERS FOR ASSESSING EXPLANT ORGAN VIABILITY Final Rejection University of Newcastle Upon Tyne
17996478 HIGH-THROUGHPUT SEROLOGY ASSAY Non-Final OA INANOVATE, INC.
17996182 METHOD FOR ENRICHING EXOSOMES Non-Final OA THERAWIS DIAGNOSTICS GMBH
17294931 ANTIBODY CONJUGATE Non-Final OA FUJIREBIO INC.
17628749 Apparatus and Method for Testing the Health Condition of Animals and/or Human Beings Final Rejection ProTEM Services Limited
17620425 A METHOD FOR DETECTING AN ANALYTE Non-Final OA Psyros Diagnostics Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month